COMMUNIQUÉS West-GlobeNewswire

Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
31/07/2026
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or [...]
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
31/07/2026
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Radiopharm Theranostics Reports Business Update
31/07/2026
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial of [...]
Ocugen to Participate in Upcoming August Investor Conferences
31/07/2026
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
31/07/2026
Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, [...]
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
31/07/2026
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: [...]
J-Star Holding Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
31/07/2026
TAICHUNG CITY, Taiwan, July 31, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), today announced that it has received a written decision from the Nasdaq Hearings Panel [...]
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
31/07/2026
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 [...]
Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
31/07/2026
–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– TUCSON, Ariz., July 31, 2026 (GLOBE NEWSWIRE) -- [...]
Jushi Holdings Inc. Completes Redomicile from British Columbia to Nevada
31/07/2026
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) ( OTCQX: JUSH ), a vertically integrated, multi-state cannabis operator, today announced the completion of [...]
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
31/07/2026
Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as [...]
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
31/07/2026
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by $0.1 million, or 0. [...]
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
31/07/2026
TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Vistagen Appoints Douglas J. Williamson to its Board of Directors
31/07/2026
Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen ( [...]
Cerenome Launches as an Integrated CNS Oncology Company
31/07/2026
Formerly known as Plus Therapeutics, Cerenome integrates precision diagnostics, targeted therapeutics, and artificial intelligence to improve how CNS cancers are detected, treated, and understood HOUSTON, July 31, 2026 [...]
Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results
31/07/2026
Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026 SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated all remaining warrant [...]
NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange
31/07/2026
Boca Raton, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company") (Nasdaq: NMAD), a leader in transportable, utility-grade battery energy storage systems through its wholly owned [...]
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
31/07/2026
SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
31/07/2026
HIGHLIGHTS A manuscript describing comprehensive preclinical studies of narmafotinib in models of pancreatic cancer is now available online. The findings provide further evidence of narmafotinib's ability to target [...]

Pages